PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2016 September 13; 7(37): 58717–58727.
Published online 2016 August 11. doi:  10.18632/oncotarget.11227
PMCID: PMC5312270

PDCD4 is a CSL associated protein with a transcription repressive function in cancer associated fibroblast activation

Abstract

The Notch/CSL pathway plays an important role in skin homeostasis and carcinogenesis. CSL, the key effector of canonical Notch signaling endowed with an intrinsic transcription repressive function, suppresses stromal fibroblast senescence and Cancer Associated Fibroblast (CAF) activation through direct down-modulation of key effector genes. Interacting proteins that participate with CSL in this context are as yet to be identified. We report here that Programmed Cell Death 4 (PDCD4), a nuclear/cytoplasmic shuttling protein with multiple functions, associates with CSL and plays a similar role in suppressing dermal fibroblast senescence and CAF activation. Like CSL, PDCD4 is down-regulated in stromal fibroblasts of premalignant skin actinic keratosis (AKs) lesions and squamous cell carcinoma (SCC). While devoid of intrinsic DNA binding capability, PDCD4 is present at CSL binding sites of CAF marker genes as well as canonical Notch/CSL targets and suppresses expression of these genes in a fibroblast-specific manner. Thus, we propose that PDCD4 is part of the CSL repressive complex involved in negative control of stromal fibroblasts conversion into CAFs.

Keywords: PDCD4, Notch/CSL signaling, transcription repression, squamous cancer, CAFs

INTRODUCTION

Notch/CSL signaling is an important form of cell-cell communication with an established pro-differentiation and tumor suppressing function in the epidermal compartment of the skin [1]. This pathway plays also an important role in the dermal compartment. In particular, deletion or silencing of the CSL gene in dermal fibroblasts, of both mouse and human origin, results in activation of a CAF phenotype, with expression of mitogenic and pro-inflammatory cytokines and in vivo induction of keratinocyte tumor formation [2]. More recent work has shown that loss of CSL signaling in dermal fibroblasts results also in impaired proliferation and senescence, providing a molecular underpinning to previous findings that senescence of stromal cells and activation of a CAF phenotype are closely associated events [3].

CSL is the key mediator of canonical Notch activation at the level of transcription [4]. Under basal conditions, CSL functions as a repressor of transcription in association with co-repressors like nCor1/nCor2, SMART, histone deacetylase (HDACs) and Skip. Nuclear translocation and physical binding of the activated Notch intracellular domain (NICD) converts CSL from a transcription repressor to an activator, replacing associated co-repressors with co-activators like Mastermind-like (MAML) proteins and histone acetylases (HATs) [5]. Components of these classical CSL co-repressor and co-activator complexes have been extensively studied at both functional and ultra-structural/molecular levels [6]. Another CSL-interacting protein called RBPj-interacting and tubulin associated (RITA) has also been identified that act as a negative modulator of Notch/CSL signaling through a different mechanism, i.e. promoting CSL export from the nucleus [7]. Additional CSL-interacting proteins are likely to exist, which may play an important role in both canonical and non-canonical Notch signaling and other cell type-specific CSL functions.

PDCD4 is known as a pro-apoptotic and tumor-suppressing gene [8, 9]. Over-expression of PDCD4 inhibits tumor growth and metastasis [10], whereas PDCD4 knockout mice develop spontaneous tumors (lymphomas) [11]. Biochemically, PDCD4 can function as an inhibitor of mRNA translation of specific target genes by interacting with the eukaryotic initiation factor 4A (eIF4A) and suppressing its function [12]. In this context, mucin 1 (MUC1), an oncoprotein that is aberrantly expressed in human cancers, is a translational target of PDCD4 [13], suggesting that PDCD4 acts as a tumor suppressor by inhibiting oncoprotein translation. However, PDCD4 can also affect gene transcription. For instance, it has been reported to modulate c-Jun activity by interacting and blocking its phosphorylation, thus inhibiting AP-1 dependent transcription [14]. PDCD4 can also interact directly with the transcription factor Twist1, a key regulator of CAFs [15], interfering with its DNA binding [16]. PDCD4 mRNA is down-regulated by miR-21, and miR-21-mediated PDCD4 suppression is required for the survival of Notch-driven T-cell leukemia [17]. Of relevance for the present study, PDCD4 down-regulation by TGF-β-induced miR-21 induction was also implicated in up-regulation of the CAF marker αSMA through as yet unidentified mechanisms in differentiating myofibroblasts [18].

We report here that PDCD4 is a novel CSL interactor of functional relevance in human dermal fibroblasts (HDFs). Silencing of PDCD4 in these cells reproduces the effects of loss of CSL, leading to induction of cellular senescence and conversion into CAFs with tumor enhancing properties. While devoid of intrinsic DNA binding activity, PDCD4 is found at the promoter regions of Notch/CSL target genes and controls expression of these genes in a fibroblast-specific manner. Overall, the findings indicate that PDCD4 is part of the CSL repressive complex involved in negative control of stromal fibroblasts to CAF conversion.

RESULTS

Endogenous interaction of PDCD4 with CSL

Screening of a yeast two-hybrid cDNA library with a CSL bait pointed to PDCD4 as a potential interactor. No direct binding was detected after over-expression of the two proteins in an exogenous system. However, a weak but consistent association between endogenous PDCD4 and CSL was found by co-immunoprecipitation assays with nuclear extracts derived from HDFs (Figure (Figure1A).1A). For independent confirmation, we performed proximity ligation assays (PLA) for detection and localization of protein-protein interactions. Positive punctate signals resulting from the close juxtaposition of the antibodies were found in HDFs, with > 6 folds reduction in HDFs with CSL gene silencing as control of specificity (Figure (Figure1B).1B). Nuclear co-localization of the two proteins was also observed by double immunofluorescence analysis of HDFs (Figure (Figure1C1C).

Figure 1
Endogenous PDCD4/CSL association and co-localization

PDCD4 gene silencing reproduces the effects of CSL loss in induction of CAF markers and Notch target genes

CSL gene silencing in HDFs leads to premature senescence together with acquisition of a CAF phenotype [3]. Similarly, PDCD4 gene silencing triggered cellular senescence, as assessed by reduced clonogenecity (Figure (Figure2A)2A) and increased Senescence Associate β-galactosidase (SA β-gal) (Figure (Figure2B),2B), and resulted in the concomitant induction of senescence- and CAF-determinant genes (Figure (Figure2C2C and and2D2D).

Figure 2
PDCD4 as negative regulator of dermal fibroblast senescence and CAF activation

In parallel with the increase of senescence- and CAF-determinant gene expression, down-modulation of PDCD4 expression in HDFs resulted in induction of the “canonical” Notch/CSL targets HES1 and HEY1 (Figure (Figure2E),2E), indicating that PDCD4 functions also as a negative co-regulator of these genes. Interestingly, up-regulation of these genes by both CSL and PDCD4 gene silencing was observed in HDFs and osteosarcoma (fibroblast-like) cell line Saos-2 cells, but not human primary keratinocytes (HKCs) or HeLa cells (Figure (Figure2F).2F). Only genes to which CSL is constitutively bound are induced when CSL levels decrease and differential binding of CSL to target genes can depend, among other things, on its expression levels, which can vary among cell types. Consistent with this possibility, immunoblot analysis showed consistently higher levels of CSL expression in multiple HDF strains and Saos-2 cells than in HKCs and HeLa cells, with an opposite pattern of PDCD4 expression (Figure (Figure2G2G and and2H2H).

PDCD4 is a part of the CSL repressive complex in controlling gene transcription

CSL has an intrinsic transcription repressive function and the expression of target genes to which it binds with high affinity is induced when levels of CSL decrease [19, 20]. PDCD4 is devoid of intrinsic DNA binding activity. However, an attractive possibility is that PDCD4 may associate with CSL at specific target genes and affect their expression. Chromatin immunoprecipitation (ChIP) assay showed the binding of PDCD4 to the promoter regions of CAF genes, such as PTGS2 and IL6, at the same sites as CSL binds and also to the promoter region of canonical Notch target HES1 (Figure (Figure3A).3A). PDCD4 association to CSL binding region of HES1 was also found in Saos-2 cells (Figure (Figure3B).3B). Importantly, we found that PDCD4 binding to these genes was lost in CSL-silenced HDFs, indicating that it is CSL-dependent (Figure (Figure3C3C).

Figure 3
Convergent binding of PDCD4 and CSL to common target genes

To further probe into the function of PDCD4, we assessed the consequences of its down-modulation on binding of CSL to its target genes. PDCD4 silencing did not change the binding of CSL to the promoter regions of IL6 and HES1 (Figure (Figure3D),3D), but resulted in increased levels of H3K27ac, a mark of activated chromatin (Figure (Figure3E),3E), consistent with PDCD4 being part of the CSL transcription repressive complex.

In vivo role of PDCD4 in CAF activation

To assess whether the above findings are of in vivo significance, we started by assessing the level of PDCD4 expression in stromal fibroblasts in premalignant or malignant lesions. Laser capture microdissection (LCM) analysis showed that PDCD4 was down-regulated in stromal fibroblasts underlying premalignant skin actinic keratosis (AKs) lesions relative to fibroblasts of adjacent unaffected skin (Figure (Figure4A),4A), and in stromal cells of in situ SCC relative to those of normal individuals (Figure (Figure4B4B).

Figure 4
PDCD4 expression is down-regulated in stromal fibroblasts of premalignant and malignant keratinocitic lesions

A key feature of CAFs is their ability to enhance proliferation of neighboring cancer cells. Accordingly, HDFs plus/minus PDCD4 gene silencing were tested by intradermal tumorigenicity assays with a keratinocyte-derived SCC cell line (SCC13). Tumor growth was enhanced when SCC13 cells were injected into mouse back skin with HDFs with PDCD4 gene silencing (Figure (Figure5A).5A). Tumors formed in the presence of HDFs with PDCD4 knockdown had higher cellularity and Ki67 proliferative index than with controls (Figure (Figure5B).5B). The same combination of cells was tested by alternative tumorigenicity assay based on injection into mouse ears. Histological analysis revealed that SCC13 cells forms tumors with higher cellularity when admixed with HDFs with PDCD4 knockdown, whereas tumors formed with control HDFs showed large empty or necrotic areas associated with the terminal differentiation cornification process (Figure (Figure5C).5C). In addition, greater positivity of the Ki67 proliferative index as well as the p63 proliferative marker was found in lesions formed with HDFs with PDCD4 silencing, while expression of the involucrin and loricrin differentiation marker was less (Figure 6A, 6B and Supplementary Figure 2A), showing tumors formed with HDFs with PDCD4 silencing contain more undifferentiated tumor cells. Furthermore, expression of key CAF markers, such as αSMA, periostin, and tenascin C, was increased in tumors with HDFs with PDCD4 silencing (Figure (Figure6C6C and Supplementary Figure 2B).

Figure 5
PDCD4 depleted fibroblasts enhance tumorigenic behavior of keratinocyte-derived SCC cells
Figure 6
Dermal fibroblasts with PDCD4 gene silencing promote formation of SCC with higher proliferative index and suppressed differentiation

Thus, PDCD4 exerts a significant in vivo function in suppression of CAF activation, which parallels that of CSL.

DISCUSSION

The CSL protein functions as a transcription regulator in concert with various co-repressors or co-activators [5]. Besides the CSL associated proteins involved in canonical Notch-dependent control of transcription, there are others with distinct or separate functions. For instance, the CSL-interacting protein DDX5 plays a more peripheral role enhancing formation of the CSL co-activator complex [21, 22], while the pancreas-specific transcription factor 1 (Ptf1) interacts and functions together with CSL independently of Notch signaling [23]. The present findings indicate that PDCD4 is also connected with CSL function, in a cell type specific manner impinging on negative control of stromal fibroblasts to CAF activation. Interestingly, no direct binding was detected after over-expression of the two proteins in a heterologous system, which suggests that their interaction requires other intermediate proteins. However, the molecular mechanism by which PDCD4 controls CSL repressive complex formation needs further investigation. SIRT1 and LSD1 proteins were recently found as a co-repressor component of CSL/Notch target genes with histone modifying activity [24] and it will be very interesting to assess whether PDCD4 is part of this new complex.

Cancer-associated fibroblasts (CAFs) are well known to support tumor growth by secreting growth factors/cytokines [25, 26] and also by providing energy-rich metabolites [27]. Many signaling pathways and transcription factors have been implicated in control of CAF gene expression [28], However, surprisingly little is known of the transcriptional changes involved in the early transition of normal fibroblasts into CAFs. Stromal alterations associated with cellular senescence and tissue aging can play an important role in the early stages of epithelial cancer development, with subsequent changes leading to cancer/stromal cell expansion [29]. Compromised Notch/CSL function is key at these early stages, leading to the concomitant induction of stromal fibroblast senescence and production of the “senescence messanging secretome” (SMS), a battery of tumor promoting cytokines, growth factors and matrix remodeling proteins that are a trademark of fully established CAFs [3]. Concurring with these findings, CSL is less expressed in stromal cells adjacent to skin premalignant lesions like actinic keratosis (AK) and in situ SCC relative to those of unaffected skin [3]. In parallel with CSL, we have shown here that PDCD4 expression is also decreased in stromal fibroblasts of these early lesions. Like with CSL, we have found that silencing of PDCD4 was sufficient to induced fibroblast senescence and SMS production and, importantly, enhance squamous cell tumor formation. While PDCD4 has been extensively studied in cancer cells and tissues [9], there are very limited studies on PDCD4 functions in stromal cells, specifically one implicating it in negative regulation of αSMA through unspecified mechanisms [18]. Besides associating with CSL, we have shown here that PDCD4 controls transcription of CAF effector genes as well as canonical Notch target genes in a fibroblast-specific manner with potentially important implications also for other systems in which stromal alterations are involved in control of epithelial cancer.

MATERIALS AND METHODS

Cells and viruses

HDFs and HKCs were obtained and cultured as previously described [2, 30]. Human skin samples for primary cell preparation were obtained from abdominoplasty procedures at Massachusetts General Hospital (MGH 2008-P-001742/2, Boston, Massachusetts, USA). Saos-2 and HeLa cell lines were purchased from the American Type Culture Collection (ATCC) and cultured in DMEM with 10% FBS. Human skin SCC13 cells were originally reported in [31] and cultured in serum-free keratinocyte SFM medium.

The lentiviral vectors encoding shRNA against PDCD4 (TRCN0000059081 and TRCN0000059078) were purchased from Openbiosystem. Lentiviruses were produced by cotransfection of HEK293 cells (Lipofectamine 2000, Invitrogen) with pLKO.1-shPDCD4 and lentiviral package plasmids.

Co-immunoprecipitations and western blotting

Nuclear extracts were prepared using NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific) according to manufacturer's instruction. 200 μg of nuclear fraction were incubated overnight at 4°C with PDCD4 antibodies (Cell Signaling Technology) or control non-immune IgGs. Dynabeads Protein G were incubated with the antigen-antibody complex for 4 hours at 4°C. Beads were washed three times with NP-40 buffer (20 mM Tris-HCl buffer, pH 8 containing 150 mM NaCl, 1 % NP-40, 1 % glycerol, and 2mM EDTA) and eluted in 50 ul of 2x SDS sample buffer at 95°C for 5 minutes and analysed by gel electrophoresis and immunoblotting.

For western blotting, cells were lysed using RIPA buffer (50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1mM EDTA) with protease inhibitor cocktail (Roche). Proteins were separated on NuPAGE 4-12 % Bis-Tris gels (Invitrogen) and transferred to a nitrocellulose membrane (Invitrogen). Antibodies specific to PDCD4 (Cell Signaling Technology), CSL (Cell Signaling Technology), and γ-tubulin (Sigma) were commercially obtained.

Immunofluorescence and proximity ligation assay

Cells were fixed with 4% formaldehyde and permeabilized in 0.1% Triton X-100. After blocking with 5% donkey serum in PBS, cells were incubated with primary antibody solution containing mouse monoclonal PDCD4 antibody (Santa Cruz Biotechnology) and rabbit monoclonal CSL antibody (Cell Signaling Technology). After washing, cells were incubated with goat anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa Fluor 598 antibodies (Invitrogen), then mounted with Vectashield mounting medium with DAPI (Vector Laboratories).

Proximity ligation assay was performed using Duolink PLA kit (Sigma) according to manufacturer's protocol. Briefly, cells were fixed with 4% formaldehyde and permeabilized in 0.1% Triton X-100. After blocking with PLA blocking solution, cells were incubated with primary antibody solution containing PDCD4 and CSL antibodies. After washing with PLA wash buffer, cells were incubated with PLA probes, anti-rabbit PLUS, anti-mouse MINUS, then washed, ligated, amplified by rolling circle amplification. Images were obtained with a Nikon Eclipse Ti confocal microscope.

Senescence assay and clonogenicity

For clonogenicity assay, 1000 cells were plated in 60mm dishes in triplicate and cultured for 14 days. The colonies were fixed with 70% ethanol and stained with 1% crystal violet.

Senescence β-galactosidase (SA-β-Gal) activity assays was performed using senescence-galactosidase staining kit (Cell Signaling Technology) according to manufacturer's protocol. For each strain, a minimum of 100 cells was counted.

siRNA transfection and realtime RT-PCR analysis

HDFs (4 × 105 cells) were plated in 60mm dishes 24 hours prior to transfection and transfected with siRNA using Hiperfect (Qiagen). After 72 hours of transfection, cells were removed and total RNAs were isolated using RNeasy mini kit (Qiagen) according to the manufacturer's protocol. RNAs were reverse-transcribed into cDNA using the iScript cDNA synthesis kit (Bio-Rad), then analysed in triplicate with gene-specific primers and 36β4 normalizaion. The primers used for realtime PCR analysis are listed in Supplementary Table 1. siRNAs for PDCD4 (Stealth RNAi HSS120545 and HSS120546) and CSL (Silencer Select siRNA s7252) were purchased from Invitrogen and Ambion.

Intradermal tumorigenicity assay

SCC13 cells (1 × 106 cells) were admixed with HDFs (5 × 105 cells) with shRNA-mediated silencing of PDCD4 or control in 150 μl of growth factor-reduced matrigel (BD Bioscience) and intra-dermally injected into the back skin of 6-week-old NOD/SCID mice (Taconic Farms Inc.) as previously described [30]. For the ear injection, SCC13 cells (1 × 105 cells) were admixed with equal numbers of HDFs with shRNA-mediated silencing of PDCD4 or control. Cells were resuspended in 3 μl of Hanks’ balanced salt solution and then injected intradermally into the left and right tip of the ear dermis of 10-week-old NOD/SCID mice using a Hamilton microsyringe fitted with 33 gauge needle as performed in [3]. Mice were sacrificed 3 weeks after injection and tumors were removed for analysis.

Tissue immunofluorescence was performed as before [2, 3]. Anti- ki67 antibody, anti-Vimentin antibody (Abcam), anti-p63 antibody (Santa Cruz Biotechnology), anti-Involucrin antibody (Sigma), anti-Periostin antibody (Abcam), anti-Tenascin C antibody (Santa Cruz Biotechnology), and anti-αSMA antibody (Santa Cruz Biotechnology) were used. Quantification of all images of tissue immunofluorescence staining was performed using ImageJ and Adobe Photoshop software.

All animal studies were performed following the approved Institutional animal protocol procedure (IACUC-MGH).

Laser capture microdissection (LCM)

LCM was performed as described previously [3]. Briefly, laser-captured cells from paraffin sections were collected using an Arcturus XT microdissection system (Applied Biosystems) and RNAs were purified by RNeasy FFEP kit (Qiagen). For immunofluorescence-guided LCM, frozen blocks of normal skin and in situ SCCs were freshly cut, immediately fixed and blocked. Sections were incubated with a mixture of fluorescein isothiocyanate (FITC)-conjugated antibodies against PDGFRα (Santa Cruz Biotechnology) and propidium iodide. The air-dried sections were then used for fluorescence-guided LCM using an Arcturus XT microdissection system as before. RNA samples were analysed in triplicate with gene-specific primers.

Chromatin immunoprecipitation (ChIP)

ChIP assays were performed as previously described [3]. Briefly, cells were cross-linked with 1% formaldehyde and chromatin fragmentation was done by sonication using a Bioruptor (Cosmo-Bio Diagenode). Fragmented chromatins were diluted 10-fold with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 2mM EDTA, 55mM Tris-HCl, pH 7.9, 167mM NaCl) and immunoprecipitated with PDCD4 antibody, CSL antibody or H3K27Ac antibody (Cell Signaling Technology). The primers used for realtime PCR analysis are listed in Supplementary Table 1.

Statistics

Data are presented as mean ± standard deviation (s.d.), mean ± standard error of the mean (s.e.m.). All realtime RT-PCR samples were tested in triplicate, and statistical significance of the results was assessed by two-tailed unpaired or paired t-test. P-value of < 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIAL TABLE AND FIGURES

Acknowledgments

We wish to thank Sandro Goruppi for discussions throughout this study and Shanell Moijta for technical support with histology.

Footnotes

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

GRANT SUPPORT

The work was supported by Grants from the National Institutes of Health (R01AR039190; R01AR064786; the content not necessarily representing the official views of NIH), Swiss National Science Foundation (310030_156191/1), European Research Council (26075083) and OncoSuisse (OCS-2922-02-2012 and KFS-3301-08-2013) to GPD. AC is supported by an AIRC-EU FP7 Marie Curie Fellowship granted by the Italian Association for Cancer Research and the European Union FP7 Marie Curie Program.

REFERENCES

1. Dotto GP. Notch tumor suppressor function. Oncogene. 2008;27:5115–5123. [PMC free article] [PubMed]
2. Hu B, Castillo E, Harewood L, Ostano P, Reymond A, Dummer R, Raffoul W, Hoetzenecker W, Hofbauer GF, Dotto GP. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell. 2012;149:1207–1220. [PMC free article] [PubMed]
3. Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski WW, Swartz MA, Brisken C, et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nature cell biology. 2015;17:1193–1204. [PMC free article] [PubMed]
4. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216–233. [PMC free article] [PubMed]
5. Kovall RA, Blacklow SC. Mechanistic insights into Notch receptor signaling from structural and biochemical studies. Current topics in developmental biology. 2010;92:31–71. [PubMed]
6. Kovall RA. More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene. 2008;27:5099–5109. [PubMed]
7. Wacker SA, Alvarado C, von Wichert G, Knippschild U, Wiedenmann J, Clauss K, Nienhaus GU, Hameister H, Baumann B, Borggrefe T, Knochel W, Oswald F. RITA, a novel modulator of Notch signalling, acts via nuclear export of RBP-J. EMBO J. 2011;30:43–56. [PubMed]
8. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene. 1995;166:297–301. [PubMed]
9. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biology of the cell / under the auspices of the European Cell Biology Organization. 2009;101:309–317. [PubMed]
10. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer research. 2005;65:6034–6041. [PubMed]
11. Hilliard A, Hilliard B, Zheng SJ, Sun H, Miwa T, Song W, Goke R, Chen YH. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. Journal of immunology. 2006;177:8095–8102. [PubMed]
12. Waters LC, Strong SL, Ferlemann E, Oka O, Muskett FW, Veverka V, Banerjee S, Schmedt T, Henry AJ, Klempnauer KH, Carr MD. Structure of the tandem MA-3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: molecular mechanisms of a tumor suppressor. The Journal of biological chemistry. 2011;286:17270–17280. [PMC free article] [PubMed]
13. Jin C, Rajabi H, Rodrigo CM, Porco JA, Jr, Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2013;32:2179–2188. [PMC free article] [PubMed]
14. Bitomsky N, Bohm M, Klempnauer KH. Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene. 2004;23:7484–7493. [PubMed]
15. Lee KW, Yeo SY, Sung CO, Kim SH. Twist1 is a key regulator of cancer-associated fibroblasts. Cancer research. 2015;75:73–85. [PubMed]
16. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer research. 2009;69:3148–3156. [PubMed]
17. Junker F, Chabloz A, Koch U, Radtke F. Dicer1 imparts essential survival cues in Notch-driven T-ALL via miR-21-mediated tumor suppressor Pdcd4 repression. Blood. 2015;126:993–1004. [PubMed]
18. Yao Q, Cao S, Li C, Mengesha A, Kong B, Wei M. Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. International journal of cancer. 2011;128:1783–1792. [PubMed]
19. Castel D, Mourikis P, Bartels SJ, Brinkman AB, Tajbakhsh S, Stunnenberg HG. Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev. 2013;27:1059–1071. [PubMed]
20. Johnson JE, Macdonald RJ. Notch-independent functions of CSL. Curr Top Dev Biol. 2011;97:55–74. [PubMed]
21. Lin S, Tian L, Shen H, Gu Y, Li JL, Chen Z, Sun X, You MJ, Wu L. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia. Oncogene. 2013;32:4845–4853. [PMC free article] [PubMed]
22. Jung C, Mittler G, Oswald F, Borggrefe T. RNA helicase Ddx5 and the noncoding RNA SRA act as coactivators in the Notch signaling pathway. Biochimica et biophysica acta. 2013;1833:1180–1189. [PubMed]
23. Beres TM, Masui T, Swift GH, Shi L, Henke RM, MacDonald RJ. PTF1 is an organ-specific and Notch-independent basic helix-loop-helix complex containing the mammalian Suppressor of Hairless (RBP-J) or its paralogue, RBP-L. Molecular and cellular biology. 2006;26:117–130. [PMC free article] [PubMed]
24. Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, Naar AM. A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Molecular cell. 2011;42:689–699. [PMC free article] [PubMed]
25. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303:848–851. [PubMed]
26. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119–150. [PubMed]
27. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell cycle. 2009;8:3984–4001. [PubMed]
28. Dotto GP. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J Clin Invest. 2014;124:1446–1453. [PMC free article] [PubMed]
29. Campisi J. Cellular senescence: putting the paradoxes in perspective. Current opinion in genetics & development. 2011;21:107–112. [PMC free article] [PubMed]
30. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, Devgan V, Lieb J, Raffoul W, Hohl D, Neel V, Garlick J, Chiorino G, Dotto GP. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes & development. 2007;21:562–577. [PubMed]
31. Restivo G, Nguyen BC, Dziunycz P, Ristorcelli E, Ryan RJ, Ozuysal OY, Di Piazza M, Radtke F, Dixon MJ, Hofbauer GF, Lefort K, Dotto GP. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. The EMBO journal. 2011;30:4571–4585. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC